Biomarkers in radiation oncology

Biomarkers in Medicine

Volumn 2, Issue 2, 2008, Pages 155-163

  Russo, Andrea L ^a,b   Citrin, Deborah ^a   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Biomarker; Immunohistochemistry; MMP 2; Rad51; Radiation; Urine; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHITINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GELATINASE A; PROTEIN MDM2; PROTEIN P53; RAD51 PROTEIN; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; VASCULOTROPIN;

BLOOD ANALYSIS; DIAGNOSTIC ACCURACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; NONHUMAN; ONCOLOGY; OROPHARYNX CARCINOMA; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; TISSUE SECTION; TREATMENT OUTCOME; TUMOR BIOPSY; URINALYSIS;

MURINAE;

EID: 44449100164     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.2.155     Document Type: Review

References (36)

1. Clark GM: Prognostic and predictive factors. In: Diseases of the Breast (3rd Edition). Harris JR, Lippman ME, Morrow M, Osborne CK (Eds). Lippincott Williams & Wilkins, PA, USA 489-514 (2000).
2. Marchetti F, Coleman MA, Jones IM, Wyrobek AJ: Candidate protein biodosimeters of human exposure to ionizing radiation. Int. J. Radiat Biol. 82(9), 605-639 (2006).
3. Gorski DH, Beckett MA, Jaskowiak NT et al.: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59(14), 3374-3378 (1999).
4. Haffty BG, Glazer PM: Molecular markers in clinical radiation oncology. Oncogene 22(37), 5915-5925 (2003).
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Glon M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97(16), 1180-1184 (2005).
6. Parikh RR, Yang Q, Haffty BG: Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 109(3), 566-573 (2007).
7. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG: Prognostic significance of vascular endothelial growth factor protein levels in oral and aropharyngeal squamous cell carcinoma. J. Clin. Oncol. 18(10), 2046-2052 (2000).
8. Khorana AA, Hu YC, Ryan CK, Komorowski RA, Hostetter G, Ahrendt SA: Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. J. Gastrointest. Surg. 9(7), 903-911 (2005).
9. Lee CM, Shrieve DC, Zempolich KA et al.: Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phospharylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 99(2), 415-421 (2005).
10. Barker FG 2nd, Simmons ML, Chang SM et al.: EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 51(2), 410-418 (2001).
11. Chakravarti A, Seiferheld W, Tu X et al.: Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 62(2), 318-327 (2005).
12. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA: Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol. Biomarkers Prev. 15(2), 194-202 (2006).
13. Johansen JS, Jensen BV, Roslind A, Price PA: Is YKL-40 a new therapeutic target in cancer? Expert Opin. Ther. Targets 11(2), 219-234 (2007).
14. Pelloski CE, Mahajan A, Maor M et al.: YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 11(9), 3326-3334 (2005).
15. Toledo F, Wahl GM: MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int. J. Biochem. Cell Biol. 39(7-8), 1476-1482 (2007).
16. Khor LY, Desilvio M, Al-Saleem T et al.: MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 104(5), 962-967 (2005).
17. Cao C, Shinohara ET, Subhawong TK et al.: Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol. Cancer Ther. 5(2), 411-417 (2006).
18. Baumann P, West SC: Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem. Sci. 23(7), 247-251 (1998).
19. Vispe S, Cazaux C, Lesca C, Defais M: Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 26(12), 2859-2864 (1998).
20. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T: In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem. Biophys. Res. Commun. 245(2), 319-324 (1998).
21. Maacke H, Jost K, Opitz S et al.: DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19(23), 2791-2795 (2000).
22. Maacke H, Opitz S, Jost K et al.: Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int. J. Cancer 88(6), 907-913 (2000).
23. Takenaka T, Yoshino I, Kouso H et al.: Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer 121(4), 895-900 (2007).
24. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW: Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int. J. Oncol. 28(5), 1113-1119 (2006).
25. Hannay JA, Liu J, Zhu QS et al.: Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/ activator protein 2 transcriptional regulation. Mol. Cancer Ther. 6(5), 1650-1660 (2007).
26. Kim MK, Cho KJ, Kwon GY et al.: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur. J. Cancer 44(1), 54-60 (2008).
27. Lee HW, Han JH, Kim JH et al.: Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 59(1), 95-104 (2008).
28. Hormigo A, Gu B, Karimi S et al.: YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res. 12(19), 5698-5704 (2006).
29. Chan LW, Moses MA, Goley E et al.: Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J. Clin. Oncol. 22(3), 499-506 (2004).
30. Stefanidakis M, Koivunen E: Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 108(5), 1441-1450 (2006).
31. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58(7), 1395-1399 (1998).
32. Angenete E, Langenskiold M, Falk P, Ivarsson ML: Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation. Int. J. Colorectal Dis. 22(6), 667-674 (2007).
33. Menard C, Johann D, Lowenthal M et al.: Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res. 66(3), 1844-1850 (2006).
34. Compton C: Getting to personalized cancer medicine: taking out the garbage. Cancer 110(8), 1641-1643 (2007).
35. Kirk MJ, Hayward RM, Sproull M et al.: Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens. J. Cell Mol. Med. (2007) (Epub ahead of print).
36. Hayward RM: Post-collection, pre-measurement variables affecting VEGF levels in urine bio-specimens. J. Cell Mol. Med. (2008) (In Press).